Watson and Amgen

Quote

Anonymous

Guest
Watson will be playing a prominent role in promotion of bone and inflammation products for Amgen. Watson is better suited to competing in generic markets and will be the key partner in bio-similars for products versus Enbrel. It will also allow Amgen to offset the huge costs associated with the bone sales force and promotion costs associated with Amgen. Watson sales management has been informed about this already and were told that Amgen would be informed at their first of year sales meetings. It will provide consolidation and eliminate redundancy (people) from both bone and inflammation.
 






F.Y.I
Watson has a limited sales force and they focus on account calls hospital formulary staff and purchasing agents, and pharmacist. they do not call directly on providers. The agreement with Amgen is for production of bio sim only in onc.

Enbrel is not going bio sim since the patent extension and bhbu is not going to be partnered with any external companies.
 






Anonymous said:
F.Y.I
Watson has a limited sales force and they focus on account calls hospital formulary staff and purchasing agents, and pharmacist. they do not call directly on providers. The agreement with Amgen is for production of bio sim only in onc.

Enbrel is not going bio sim since the patent extension and bhbu is not going to be partnered with any external companies.
Click to expand...

You are exactly right...
 












Anonymous said:
both mistaken. work flow, and project name started about 4 weeks ago - in advance of the release. watson has already announced plans to expand its sales force in the start of Q2 of this year. its coming.
Click to expand...

Dude, whats coming????? If i was the ceo, i will give watson all the bulk so they can do the fill and finish process for about half the price we currently do it for
 






Anonymous said:
Dude, whats coming????? If i was the ceo, i will give watson all the bulk so they can do the fill and finish process for about half the price we currently do it for
Click to expand...

that is one portion of the plan, from manufacturing to sales they will be playing a larger role toward what will eventually be a full merger
 






Watson market cap is 8.01 Billion, wouldn't be much of a merger more like an acquisition and it won't even be that. They don't have a market presence, intellectual property, or pipeline....pretty much the only 3 reasons a biotech would acquire.
the only reason we entered into an agreement with them is so we can disassociate ourselves from "generic" or "biosimiliars" but still realize the gain from it.


Anything is a troll trying to create confusion and distract us.
 






Anonymous said:
Watson market cap is 8.01 Billion, wouldn't be much of a merger more like an acquisition and it won't even be that. They don't have a market presence, intellectual property, or pipeline....pretty much the only 3 reasons a biotech would acquire.
the only reason we entered into an agreement with them is so we can disassociate ourselves from "generic" or "biosimiliars" but still realize the gain from it.


Anything is a troll trying to create confusion and distract us.
Click to expand...

Simply wrong. Merger for cash and tax purposes. This has been in development for a very long time, not as simple as having a generic arm. Try to create any misinformation that you want, doesn't change the facts.
 
























Top Bottom
Back
Quote